期刊文献+

骨肉瘤化疗若干热点问题 被引量:4

原文传递
导出
摘要 辅助化疗和新辅助化疗使骨肉瘤患者5年生存率从35年前的不足20%提高到现在的60%以上。骨肿瘤的化疗可以追溯到1961年。但直到Rosen、Jaffe等相继将阿霉素、甲氨蝶呤用于骨肉瘤的治疗,骨肉瘤辅助化疗(术后化疗)才真正拉开了序幕。但近15年来,骨肉瘤生存率处于平台期,为此,国际上众多研究机构设计进行了许多临床试验,试图进一步提高其生存率,本文结合这些试验,对骨肉瘤化疗中存在的几个热点问题进行综述。
出处 《中华外科杂志》 CAS CSCD 北大核心 2009年第14期1108-1110,共3页 Chinese Journal of Surgery
  • 相关文献

参考文献33

  • 1牛晓辉,蔡槱伯,张清,郝林,丁易.ⅡB期肢体骨肉瘤189例综合治疗临床分析[J].中华外科杂志,2005,43(24):1576-1579. 被引量:41
  • 2Evans AE.Mitomyein C.Cancer Chemother Rep,1961,14:1-9.
  • 3Rosen G,Mareove RC,Caparros B,et al.Primary osteogenic sarcoma:the rationale for preoperative chemotherapy and delayed surgery.Cancer,1979,43:2163-2177.
  • 4Winkler K,Bielack SS,Delling G,et al.Treatment of osteosarcoma:experience of the Cooperative Osteosarcoma Study Group (COSS).Cancer Treat Res,1993,62:269-277.
  • 5Meyers PA,Heller G,Healey J,et al.Chemotherapy for nonmetastatic osteogenic sarcoma:the Memorial Sloan-Kettering experience.J Clin Oncol,1992,10:5-15.
  • 6Bielack SS,Kempf-Bielack B,Heise U,et al.Combined modality treatment for osteosarcoma occurring as a second malignant disease.Cooperative German-Austrian -Swise Osteosarcoma Study Group.J Clin Oncol,1999,17:1164.
  • 7Goorin AM,Schwartzentruber DJ,Devidas M,et al.Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmctastatic osteosarcoma:Pediatric Oncology Group Study POG-8651.J Clin Oncol,2003,21:1574-1580.
  • 8Huvos A.Pathologic assesment of preoperative (neoadjuvant) chemotherapy//Bone tumors:diagnosis,treatment and prognosis.2nd edition.Philadelphia:WB Saunders,1991:122-128.
  • 9Bielack SS,Kempf-Bielack B,Delling G,et al.Prognostic factors in high-grade osteosarooma of the extremities or trunk:an analysis of1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.J Clin Oncol,2002,20:776-790.
  • 10Lewis U,Nooij MA,Whelan J,et al.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy:a randomized phase Ⅲ trial of the European Osteosarooma Intergroup.J Nail Cancer Inst,2007,99:112-128.

二级参考文献7

共引文献57

同被引文献57

  • 1李秀贺,章萍.阿拓莫兰治疗儿童大剂量甲氨蝶呤化疗性肝损害临床观察[J].天津医科大学学报,2004,10(3):423-424. 被引量:2
  • 2李秀贺,张平.硫普罗宁防治大剂量甲氨蝶呤致儿童肝损害临床观察[J].药物不良反应杂志,2004,6(5):303-305. 被引量:10
  • 3厉有名.药物性肝损害的临床类型及诊断策略[J].中华肝脏病杂志,2004,12(7):445-446. 被引量:252
  • 4徐万鹏;冯传汉.骨科肿瘤学[M]北京:人民军医出版社,2001623-624.
  • 5陈刚.治疗药物监测[M]北京:人民军医出版社,1988425-428.
  • 6陈文彬;潘祥林.诊断学[M]北京:人民卫生出版社,2008368.
  • 7Guijarro MV, Ghivizzani SC, Gibbs CP. Animal models in osteosar- coma [J]. Frontiers in Oncology, 2014, 4: 189.
  • 8Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic ad- juvant treatment for osteosarcoma: where do we stand?[J]. Europe- an Journal of Cancer, 2011, 47: 2431-2445.
  • 9Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma [J]. Current opinion in pharmacology, 2014, 16: 15-23.
  • 10Bemthal NM, Federman N, Eilber FR, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemo- therapy in patients with high-grade, operable osteosarcoma [J]. Can- cer, 2012,118(23): 5888-5893.

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部